Use of quantitative hepatitis B surface antigen with hepatitis B virus DNA in clinical practice.
作者信息
Wong Grace Lai-Hung, Chan Henry Lik-Yuen
机构信息
Institute of Digestive Disease and the Chinese University of Hong Kong, Hong Kong SAR, China.
Department of Medicine and Therapeutics, the Chinese University of Hong Kong, Hong Kong SAR, China.
出版信息
Clin Liver Dis (Hoboken). 2013 Mar 1;2(1):8-10. doi: 10.1002/cld.165. eCollection 2013 Feb.
Abstract
摘要
相似文献
1
Use of quantitative hepatitis B surface antigen with hepatitis B virus DNA in clinical practice.定量乙型肝炎表面抗原与乙型肝炎病毒DNA在临床实践中的应用。
Clin Liver Dis (Hoboken). 2013 Mar 1;2(1):8-10. doi: 10.1002/cld.165. eCollection 2013 Feb.
2
Quantitative Hepatitis B e Antigen: A Better Predictor of Hepatitis B Virus DNA than Quantitative Hepatitis B Surface Antigen.乙肝e抗原定量：比乙肝表面抗原定量更好的乙肝病毒DNA预测指标。
Clin Lab. 2018 Apr 1;64(4):443-449. doi: 10.7754/Clin.Lab.2017.170916.
3
Changing serum levels of quantitative hepatitis B surface antigen and hepatitis B virus DNA in hepatitis B virus surface antigen carriers: a follow-up study of an elderly cohort.乙肝表面抗原携带者血清中定量乙肝表面抗原和乙肝病毒DNA水平的变化：一项老年队列的随访研究
Kaohsiung J Med Sci. 2015 Feb;31(2):102-7. doi: 10.1016/j.kjms.2014.11.002. Epub 2014 Dec 4.
4
5
Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B.比较定量乙型肝炎表面抗原、乙型肝炎 e 抗原和乙型肝炎病毒 DNA 水平，预测乙型肝炎 e 抗原阳性慢性乙型肝炎患者对聚乙二醇干扰素-α-2b 治疗的病毒学应答。
Hepatol Res. 2010 Apr;40(4):269-77. doi: 10.1111/j.1872-034X.2009.00592.x. Epub 2010 Jan 11.
6
Detection of hepatitis B virus DNA in serum by polymerase chain reaction. Application for clinical diagnosis.
Gastroenterology. 1990 Sep;99(3):799-804. doi: 10.1016/0016-5085(90)90971-3.
7
Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.血清乙型肝炎表面抗原和乙型肝炎 e 抗原滴度：疾病阶段影响与病毒载量和肝内乙型肝炎病毒标志物的相关性。
Hepatology. 2010 Jun;51(6):1933-44. doi: 10.1002/hep.23571.
8
Correlation between quantitative serum HBsAg and HBV DNA test in Korean patients who showed high level of HBsAg.在 HBsAg 水平较高的韩国患者中，血清 HBsAg 定量与 HBV DNA 检测的相关性。
J Clin Pathol. 2010 Nov;63(11):1027-31. doi: 10.1136/jcp.2010.078832. Epub 2010 Sep 23.
9
The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B.慢性乙型肝炎患儿血清乙型肝炎表面抗原和乙型肝炎e抗原定量水平的重要性。
Turk J Gastroenterol. 2015 Jan;26(1):36-41. doi: 10.5152/tjg.2015.4636.
10
Occult hepatitis B virus infection in hemodialysis patients in Japan.日本血液透析患者中的隐匿性乙型肝炎病毒感染
Ther Apher Dial. 2015 Apr;19(2):125-30. doi: 10.1111/1744-9987.12241. Epub 2014 Nov 3.
引用本文的文献
1
Correlations between serum hepatitis B core-related antigen and hepatitis B surface antigen in patients with hepatitis B cirrhosis and a hepatitis B virus-DNA-negative status: a retrospective study.血清乙型肝炎核心相关抗原与乙型肝炎病毒 DNA 阴性状态乙型肝炎肝硬化患者乙型肝炎表面抗原的相关性：一项回顾性研究。
J Int Med Res. 2022 Oct;50(10):3000605221130714. doi: 10.1177/03000605221130714.
本文引用的文献
1
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.《亚太地区慢性乙型肝炎管理共识声明：2012年更新版》
Hepatol Int. 2012 Jun;6(3):531-61. doi: 10.1007/s12072-012-9365-4. Epub 2012 May 17.
2
Peginterferon therapy for chronic hepatitis B: one size fits all?聚乙二醇干扰素治疗慢性乙型肝炎：一刀切可行吗？
Gut. 2013 Feb;62(2):185-7. doi: 10.1136/gutjnl-2012-303291. Epub 2012 Sep 1.
3
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B.比较基因型 D HBeAg 阴性慢性乙型肝炎患者接受 48 周和 96 周聚乙二醇干扰素 α-2a 治疗的随机研究。
Gut. 2013 Feb;62(2):290-8. doi: 10.1136/gutjnl-2011-301430. Epub 2012 Aug 2.
4
Identifying hepatitis B carriers at low risk for hepatocellular carcinoma.识别患肝细胞癌低风险的乙肝携带者。
Gastroenterology. 2012 May;142(5):1057-60. doi: 10.1053/j.gastro.2012.03.013. Epub 2012 Mar 23.
5
Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a.使用聚乙二醇干扰素 α-2a 治疗 HBeAg 阴性患者时，第 12 周使用 HBsAg 和 HBV DNA 验证停药标准。
J Hepatol. 2012 May;56(5):1006-1011. doi: 10.1016/j.jhep.2011.12.007. Epub 2012 Jan 13.
6
Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients.乙型肝炎 e 抗原阴性慢性乙型肝炎患者乙型肝炎表面抗原血清学清除的病毒决定因素。
J Infect Dis. 2011 Aug 1;204(3):408-14. doi: 10.1093/infdis/jir283.
7
Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.乙型肝炎表面抗原定量检测：2011 年为何检测及如何检测——核心专家组报告
J Hepatol. 2011 Nov;55(5):1121-31. doi: 10.1016/j.jhep.2011.06.006. Epub 2011 Jun 28.
8
Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum.Elecsys HBsAg II 检测法与 Architect 检测法在血清中定量检测乙型肝炎表面抗原 (HBsAg) 的相关性。
J Clin Virol. 2011 Apr;50(4):292-6. doi: 10.1016/j.jcv.2010.12.008. Epub 2011 Jan 26.
9
Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.基于治疗过程中乙型肝炎表面抗原下降情况预测乙型肝炎 e 抗原阳性慢性乙型肝炎对聚乙二醇干扰素 alfa-2b 的持续应答。
Hepatology. 2010 Oct;52(4):1251-7. doi: 10.1002/hep.23844.
10
A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B.一项关于慢性乙型肝炎患者血清乙型肝炎表面抗原变化自然史的纵向研究。
Hepatology. 2010 Oct;52(4):1232-41. doi: 10.1002/hep.23803.
Zotero 插件